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background: A successful oocyte cryopreservation programme is of utmost importance where a limited number of oocytes can be
inseminated per cycle, to overcome legal and ethical issues related to embryo storage, for oocyte donation programmes and for fertility
preservation (especially for cancer patients). Vitriﬁcation has been recently proposed as an effective procedure for this purpose.
methods: In order to validate the effectiveness of oocyte vitriﬁcation a non-inferiority trial was started on sibling metaphase II (MII)
oocytes. To demonstrate the non-inferiority based on an absolute difference of 17% in the fertilization rate per sibling oocyte, a
minimum of 222 oocytes were required. After oocyte denudation, MII oocytes with normal morphology were randomly allocated to
fresh ICSI insemination or to vitriﬁcation procedure. If pregnancy was not obtained a subsequent ICSI cycle was performed with warmed
oocytes of the same cohort. In both groups, three oocytes were inseminated per cycle by ICSI procedure. Primary end-points were fertiliza-
tion rates calculated per warmed and per injected oocytes. Secondary end-points were zygote and embryo morphology.
results: A total of 244 oocytes were involved in this study. Of the 120 fresh sibling oocytes inseminated, 100 were fertilized (83.3%).
Survival rate of sibling vitriﬁed oocytes was 96.8% (120/124 oocytes). Fertilization rate after ICSI was 76.6% (95/124) per warmed oocyte
and 79.2% (95/120) per survived/inseminated oocyte. No statistical difference in fertilization rates was observed between the two groups
when calculated per sibling oocytes (absolute difference 26.73%; OR: 0.65; 95% CI ¼ 0.33–1.29; P ¼ 0.20) and per inseminated oocyte
(absolute difference 24.17%; OR: 0.76; 95% CI ¼ 0.37–1.53; P ¼ 0.50). Embryo development was also similar in both treatment
groups up till Day 2. The percentage of excellent quality embryos was 52.0% (52/100) in the fresh group and 51.6% (49/95) in the vitriﬁca-
tion group (absolute difference 20.43%; OR: 0.98; 95% CI ¼ 0.53–1.79; P ¼ 0.9). The mean age of the 40 patients included in this study
was 35.5+4.8 years (range 26–42). Fifteen clinical pregnancies were obtained in the vitriﬁcation cycles of 39 embryo transfers performed
(37.5% per cycle, 38.5% per embryo transfer), with an implantation rate of 20.2% (19/94). Three spontaneous miscarriages occurred (20%).
Twelve pregnancies are ongoing (30.0% per cycle, 30.8% per embryo transfer) beyond 12 weeks of gestation.
conclusions: Our results indicate that oocyte vitriﬁcation procedure followed by ICSI is not inferior to fresh insemination procedure,
with regard to fertilization and embryo developmental rates. Moreover, ongoing clinical pregnancy is compatible with this procedure, even
with a restricted number of oocytes available for insemination. The promising clinical results obtained, in a population of infertile patients,
need to be conﬁrmed on a larger scale.
Clinical Trials Registration number: iSRCTN60158641.
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Introduction
In Italy from March 2004 to May 2009, according to the Italian Law
No. 40 that regulates assisted reproductive technology (ART), no
more than three oocytes could be inseminated per cycle, all obtained
embryos had to be transferred, and embryo cryopreservation and
gamete donation were forbidden. Thus, no embryo selection, based
on morphological and/or genetic evaluation, was possible (Benagiano
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restrictions imposed, oocyte selection (Chamayou et al., 2006;
Rienzi et al., 2008) and cryopreservation (Borini et al., 2006a, b,
2007; La Sala et al., 2006; Levi Setti, 2006; Chamayou et al., 2006;
De Santis et al., 2007; Parmegiani et al., 2008, 2009a,b; Magli et al.,
2009) have been introduced as routine practice in Italian IVF
centres. A recent edict of the Italian Constitutional Court (151/
2009) declared that patient health is paramount, and thus embryo
freezing is constitutional, if determined by the health of the patient.
To this end, many changes have been introduced in the Italian IVF
centres. In particular, to guarantee the best treatment for patients,
the number of oocytes to be inseminated is now chosen by the phys-
ician (and not by the Parliament) according to the individual situation.
It must however be underlined that the application of oocyte cryopre-
servation is not only limited to the Italian situation; this technique is
also of paramount importance for fertility preservation (especially in
the case of cancer patients), for oocyte donation programmes, and
to help overcome ethical issues related to embryo cryopreservation.
Oocyte cryopreservation, however, still represents a great challenge
in ART (Gardner et al., 2007). The difﬁculties associated with oocyte
cryopreservation are mostly related to the special structure and
sensitivity of this cell. Differences observed in plasma membrane per-
meability to water and cryoprotectants, compared with later stages of
development, makes oocyte survival rate very low with standard
slow freezing protocols (Agca et al., 1998; Ford et al., 2000; Van
den Abbeel et al., 2007). The extreme sensitivity of the meiotic
spindle to temperature variation and to oocyte dehydration/
rehydration (Chen et al., 2004; Rienzi et al., 2004; Bianchi et al.,
2005; Coticchio et al., 2005; De Santis et al., 2007; Larman et al.,
2007; Cobo et al., 2008a; Chen and Yang, 2009) may compromise
subsequent chromosomal segregation. Precocious oocyte
activation induced by cryoprotectants exposures may disturb
future development (Larman et al., 2006; Gardner et al., 2007).
Moreover, increased risk of oocyte ageing is reported with cryopre-
servation procedure (Parmegiani et al., 2008, 2009ab). Oocyte
physiology seems also to be severely affected by cryopreservation
(Gardner et al., 2007).
Novel approaches to slow freezing have been introduced (Fabbri
et al., 2001; Borini et al., 2006a, b, 2007; Boldt et al., 2006) with
improved oocyte survival rate and subsequent embryo development.
Although these studies clearly describe a contribution of oocyte cryo-
preservation to the overall clinical success rate, they also show the
limitations of the technique in terms of implantation rate per
thawed oocyte. Very recently, reduced oocyte competence to devel-
opment was reported in frozen cycles when compared with sibling
fresh cycles (Magli et al., 2009), conﬁrming the negative impact of
slow-freezing procedure on oocyte potentiality. It is realistic to
expect that cryopreservation in general (also of later stages of devel-
opment) is less effective than fresh treatment, but the impact of the
technique should not, in our opinion, exceed a certain range to
justify its application in routine work.
As an alternative to slow freezing, vitriﬁcation procedure has been
suggested for oocyte (and embryo) cryopreservation by different
investigators (for review see Vajta and Nagy, 2006). The recent
improvements in this approach, including increased cooling and
warming rates using very small volumes and decreasing toxicity by
reducing cryoprotectants concentrations, have allowed very high
results in terms of oocyte survival, fertilization, embryo development
rates and clinical outcomes (Kuleshova et al., 1999; Kuwayama
et al., 2005; Lucena et al., 2006; Selman et al., 2006; Antinori et al.,
2007; Kuwayama 2007; Yoon et al., 2007; Cobo et al. 2008b, c,
Chian et al., 2008; Sher et al., 2008; Kim et al., 2009; Nagy et al.,
2009). Moreover, when vitriﬁed oocytes are compared simultaneously
with fresh counterparts, in an oocyte donation programme, similar
laboratory results are observed in terms of fertilization (76.3 and
82.2%, respectively), embryo development and blastocyst formation
rates (48.7 and 47.5%, respectively) (Cobo et al., 2008b).
The difference in efﬁcacy between slow freezing and vitriﬁcation
procedures may be related to the fact that vitriﬁcation has a lower
impact on oocyte physiology as compared with slow freezing
(Gardner et al., 2007). A second aspect must be considered. Most
of the published studies dealing with the oocyte vitriﬁcation procedure
are performed in oocyte donation programmes or in patients with an
extremely good prognosis (Kuwayama et al., 2005; Lucena et al., 2006;
Yoon et al. 2007; Cobo et al., 2008b, c). Although oocyte competence
with the vitriﬁcation procedure appears to have improved, further
studies are needed (designed in a prospective way) to determine
the efﬁcacy of this approach in the population of infertile patients.
The origin of the oocytes involved is, in fact, clearly a determining
factor in the results, with an obvious advantage of young donors com-
pared with older infertile women (Kim et al., 2009).
In order to validate the effectiveness of a vitriﬁcation approach for
oocyte cryopreservation a prospective comparison was thus designed
in our population of infertile patients. This study was set-up as a non-
inferiority trial with a prospective target of 240 sibling metaphase II
(MII) oocytes obtained from an estimated 40 ICSI patients (assuming
that three oocytes per patient are inseminated in the fresh and in the
vitriﬁed groups). Oocyte fertilization rates after ICSI (per warmed
oocyte and per injected oocyte) were evaluated as primary outcomes.
Secondary outcomes were pronuclear morphology and embryo
development.
Materials and Methods
Study design and outcomes measures
A randomized sibling-oocyte trial was started to evaluate the effectiveness
of oocyte vitriﬁcation when compared with fresh oocyte insemination in
terms of fertilization rate per warmed and per injected oocyte. Randomiz-
ation was performed at the moment of oocyte denudation by a different
person from the one who performed the procedure. To each normal-
appearing oocyte at MII stage a number was assigned by a computer-
generated random list (www.random.org). Oocyte numbers 1, 2 and 3
were assigned to fresh ICSI procedure while the others to vitriﬁcation pro-
cedure. The warming procedure was performed by using the subsequent
oocytes (starting from numbers 4, 5 and 6 and including other oocytes if
necessary). Only the ﬁrst warmed attempt was included in the study. By
using a paired number of transfers from each patient, where the same
number of sibling oocytes was used for insemination, differences in
patient characteristics such as female age duration and origin of infertility,
rank of trial were eliminated.
The primary efﬁcacy end-points were non-inferiority in fertilization rates
calculated per warmed and per injected oocyte. Secondary efﬁcacy
measures included pronuclear morphology and embryo development. In
addition, patient’s baseline characteristics and clinical outcomes were
documented.
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Between 2 September 2008 and 10 March 2009 consecutive patients not
older than 42 years of age, presenting more than six normal-appearing MII
oocytes and undergoing ICSI treatment with ejaculated sperm in the
Centre for Reproductive Medicine GENERA in Rome, were considered
for inclusion. To exclude potential negative paternal effect on embryo
development, surgically extracted spermatozoa and very severe oligoaste-
noteratozoospermia (motile sperm count ,500.000/ml after prep-
aration) were not included. Patients enrolled in our polar body biopsy
programme were also excluded.
The study and the informed consent were approved by the Institutional
Review Board of the Clinic.
Ovarian stimulation, oocyte collection,
denudation, evaluation and injection
Controlled ovarian hyperstimulation was performed using two different
protocols: GnRH-agonist long protocol and GnRH-antagonist protocol
as described previously (Rienzi et al., 2008).
Oocyte collection was performed at 35 h post-hCG administration.
Denudation from the cumulus oophorus was performed by a brief
exposure to 40 IU/ml hyaluronidase solution in fertilization media (Sage
In-Vitro Fertilization, Inc., Trumbull, CT, USA), followed by mechanical
removal of the corona radiata with the use of plastic pipettes of deﬁned
diameters (denuding pipette; COOK Ireland Ltd, Limerick, Ireland) in a
controlled CO2 and temperature environment (IncuChamber L-323, Ksys-
tems, Birkerod, Denmark). This procedure was performed between 37
and 40 h post-hCG administration. MII oocytes were separated from
the immature oocytes and evaluated at the stereomicroscope. Those
with dark cytoplasm, centrally located granular area, giant, with vacuoles
and/or with large polar bodies were considered of lower quality (accord-
ing to Rienzi et al., 2008) and were thus excluded from randomization.
The selected oocytes were allocated to fresh insemination or vitriﬁca-
tion, both performed immediately after denudation. According to the
Italian law in force when this study was performed, a maximum of three
oocytes were inseminated per patient in both groups. Oocytes were sub-
jected to ICSI using previously described techniques and instrumentations
(Rienzi et al., 1998). To be able to follow the developmental progression
of individual oocyte, each inseminated oocyte was cultured separately in
microdrops of 35 ml of cleavage medium under mineral oil (Sage) up to
Day 2, in MINC incubators (COOK) (hypoxic atmosphere containing
6% CO2). All obtained embryos were transferred back to the patient.
In oocyte warmed cycles, the obtained embryos were all transferred in
the course of a natural cycle. When the mean diameter of the leading fol-
licle was 17–18 mm and the endometrial thickness was .7 mm with a
triple line pattern, the ovulation was triggered. Thirty-six to forty hours
later, the oocytes were warmed and inseminated.
The luteal phase was supported by means of vaginal micronized pro-
gesterone, 400 mg/day (Progefﬁk 200 mg, Efﬁk, Cinisello Balsamo,
Milan, Italy) starting on the day of oocyte retrieval/warming and the
embryo transfers were performed 44–48 h after the microinjection
procedure.
Oocyte vitriﬁcation and warming procedures
The vitriﬁcation and warming procedures were performed according to
Kuwayama et al. (2005, 2007). Commercial kits were used (Vitriﬁcation
and Warming KIT, Kitazato BioPharma Co, Japan).
The vitriﬁcation procedure was performed at room temperature (RT).
Oocytes were ﬁrst equilibrated in 7.5% ethylene glycol (EG) and 7.5%
dimethylsulfoxide (DMSO). The equilibration was performed gradually.
After 12–15 min incubation, the oocytes (one to three,
contemporaneously) were then transferred in 1 ml of vitriﬁcation solution
(VS) containing 15% EG, 15% DMSO and 0.5 M sucrose for 1 min. The
oocytes were then placed on the Cryotop strip in a single small drop of
VS. Much care was taken to re-aspirate the excess of VS in such a way
to leave just a thin layer around each oocyte. The Cryotop was then
immediately submerged into liquid nitrogen. Finally, the plastic cap was
pulled over the Cryotop inside the liquid nitrogen and the sample was
stored submerged in liquid nitrogen.
The ﬁrst step of warming procedure was performed at 378C. The cap
was removed in liquid nitrogen and the cryotop was immediately
submerged in 1 ml of warming solution containing 1.0 M sucrose. After
1 min, oocytes were placed in 1 ml solution containing 0.5 M sucrose,
and incubated at RT for 3 min. Finally, the oocytes were washed at RT
for 6 min in two different dishes containing 1 ml basic medium, then trans-
ferred into 1 ml culture media (Cleavage media, Sage). Degenerated
oocytes were removed from the cohort.
The surviving oocytes were cultured at 378 (6% CO2 and 5% O2) in mini
Sanyo incubators (48L, MCO-5M Sanyo, Japan) for exactly 2 h before ICSI.
Pronuclear and Day 2 embryo assessment
Fertilization was assessed at 16–18 h after ICSI. Fertilized oocytes were
considered morphologically normal when two equally sized centrally
located pronuclei were visible. Asymmetry, eccentric position and/or dis-
tance between the two pronuclei were considered as abnormal patterns.
Cleaving embryos were evaluated on Day 2 after ICSI (44–46 h post-
insemination) with the use of a cumulative embryo classiﬁcation scheme
taking into account cleavage speed, blastomere symmetry, extent of frag-
mentation and the presence or absence of multinucleated blastomeres
(Rienzi et al., 2002). In accordance with this scheme an embryo was con-
sidered excellent when it scored 0–1, good when it scored 2–3, fair when
it scored 4–5 and poor quality when it scored .5.
Clinical outcome
Pregnancy was conﬁrmed by serial rise in serum HCG concentrations on
two consecutive occasions 13 days after embryo transfer. According to
Farquharson et al. (2005) the absence of an identiﬁable pregnancy on ultra-
sound examination was named ‘Biochemical pregnancy loss’. Clinical preg-
nancy was determined by ultrasound demonstration of gestational sac at 7
weeks. Miscarriage was classiﬁed as ‘early’ (before 12 weeks) or ‘late’
(after 12 weeks) according to Farquharson et al. (2005).
Implantation rate and ongoing implantation rate were deﬁned as
number of gestational sacs per transferred embryo, and number of
fetuses with heart activity beyond 12 weeks of gestation per transferred
embryo, respectively.
Sample speciﬁcations and statistical analysis
The non-inferiority margin of this study was set at 17% because this
threshold was considered to indicate clinically important differences, in
particular on the number of embryos available for transfer in our
setting. Considering a mean fertilization rate of 84%, based on our experi-
ence with ICSI procedure with selected fresh MII oocytes, the lower con-
ﬁdence limit would be not inferior to 67% for the insemination performed
with vitriﬁed oocytes. By using three oocytes for ICSI, the mean number of
fertilized oocytes in the vitriﬁed group would not fall below 2, which is the
expected number of embryos needed for transfer. It must be underlined
that in this setting the embryos are not selected.
To demonstrate the non-inferiority of vitriﬁcation procedure on fertili-
zation rate based on a maximum absolute difference of 17% with a
power of 80% and a conﬁdence of 95% (non-inferiority design with one-
sided tests performed) a minimum of 111 oocytes were required per
group (222 total). It was decided to include 40 patients (considering
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calculated number of oocytes.
Baseline characteristics (continuous data: female age, rank of trial,
baseline FSH, total dose of gonadotrophin, days of stimulation, number
of cumulus corona cell oocyte complexes retrieved, number of MII
obtained, number of embryos transferred, number of oocytes vitriﬁed,
number of oocytes warmed) are presented as absolute, mean with stan-
dard deviation (SD) and range. Categorical variables (oocyte survival,
oocyte fertilization, normal and abnormal pronuclear (PN) morphology,
1PN and 3PN occurrence, oocyte degeneration, embryo quality, clinical
pregnancy, biochemical pregnancy loss, early miscarriage, ongoing preg-
nancy, implantation rates) are presented as absolute and percentage
frequency.
Differences in frequencies of fertilization (primary outcome), pronuclear
morphology and embryo grade (secondary outcomes) were evaluated
with Pearson’s chi-squared test with Yates’ continuity correction and
Fisher’s exact test. Data are presented as odds ratio (OR), 95% conﬁ-
dence interval (95% CI), and P-value. The differences between arms are
summarized as absolute difference with 95% CI.
To verify the inﬂuence of potential confounding variables (female age,
rank of trial, baseline FSH, stimulation protocol, the total dose of gonado-
trophin, days of stimulation, number of cumulus corona cell oocyte com-
plexes retrieved, number of MII obtained) on primary outcomes, logistic
regression analysis was conduced. Moreover, McNemar’s test was used
to test whether the proportion of cycles (on a per woman basis) where
at least one of the three oocytes successfully fertilized, was equal for
both groups. Embryo scores were aggregated to the level of each
patient for each arm and a paired t-test was performed. P , 0.05 was con-
sidered statistically signiﬁcant.
All statistical analyses were performed using R version 2.8.0 (The R
Foundation for Statistical Computing). This trial has been registered and
the following number has been assigned ISRCTN60158641.
Results
Baseline characteristics and clinical
outcomes
During the study period 366 patients underwent 391 ICSI cycles with
ovarian stimulation in our centre. Twenty-four cycles were performed
in females aged .42 years old, in 182 cycles less than six normal-
appearing oocytes at MII stage were obtained, in 17 cycles testicular
sperm was used and in 11 cycles less than 500 000 motile sperm
were obtained after preparation. Polar body biopsy was performed
in two cycles, and 31 patients did not agree to sign the informed
consent. All these cases did not meet with the inclusion criteria and
were excluded from the study.
One hundred and twenty four cycles, from 124 patients (33.8% of
the treated couples) meet with the inclusion criteria. Fifty four patients
(43.2%) obtained a clinical pregnancy in the fresh cycle and were
therefore not, involved in the warming cycle during the study
period. Of these 6 had an early miscarriage (11.1%) and 48 are
ongoing (beyond 12 weeks of gestation) (38.8%). Sixty-nine sacs
were observed by ultrasound examination with an implantation rate
of 21.7% (69/318) and an ongoing implantation rate of 19.2% (61/
318).
Of the remaining 70 patients, 40 performed the ﬁrst warming cycle
during the study period and represent our patient population (per-
protocol analysis). The mean age of these included patients was
35.5+4.8 years (range 26–42). In Table I patient’s baseline charac-
teristics and cycle parameters are described. Three oocytes were inse-
minated per patient in the fresh cycle (N ¼ 120 oocytes) and the
remaining good quality oocytes were vitriﬁed (N ¼ 251; mean
6.3+2.8; range 3–14).
The fertilization rate obtained with fresh oocytes was 83.3% (100/
120). All obtained viable embryos (N ¼ 100), independently from
their morphological appearance, were transferred. The mean
number of embryos transferred per patient was 2.5+0.5 (range 1–
3). In one case no embryo was available for transfer.
One hundred twenty four oocytes were warmed in the 40 cycles
included (mean 3.1+0.3, range 3–4), of which 120 survived the pro-
cedure (96.7%). In all cases three oocytes were available for the ICSI
procedure (N ¼ 120) and 95 fertilized (79.2%). All available embryos
were transferred (N ¼ 93). Also in this group, one case was cancelled
because no embryo was available. Seventeen pregnancies were
obtained (43.6% per cycle, 45.9% per embryo transfer), two of
which had a biochemical pregnancy loss. Of the 15 clinical pregnancies
recorded (37.5% per cycle, 38.5% per embryo transfer), 3 had an early
miscarriage (20%) and 12 are ongoing (beyond 12 weeks of gestation)
(30.0% per cycle, 30.8% per embryo transfer). Nineteen gestational
sacs were observed by ultrasound examination with an implantation
rate of 20.4% (19/93) and an ongoing implantation rate of 17.2%
(16/93) (Table II).
Primary and secondary outcome measures:
fertilization rates, pronuclear morphology
and embryo development
Table III shows fertilization rates obtained per warmed oocyte and per
injected oocyte, pronuclear morphology, embryo development and
quality in the fresh ICSI group and in the vitriﬁed/warmed ICSI
group. No statistical differences were found between the two
groups for all the parameters analysed. The lower limit of the
........................................................................................
Table I Patient’s baseline characteristics and fresh
cycle parameters
Patients included
(N 5 40)
Female age (mean years+SD) 35.5+4.8
Baseline FSH (mean mU/ml+SD) 6.44+3.1
Previous IVF attempts (mean+SD) 0.58+1.0
GnRH-agonist long protocol (%) 31/40 (77.5)
Antagonist protocol (%) 9/40 (22.5)
Days of stimulation (mean+SD) 10.8+1.95
Total gonadotrophin amount IU
(mean+SD)
2201.65+765.7
Number of CCOCs retrieved
(mean+SD)
13.3+4.5
Number of MII oocytes (mean+SD) 10.7+3.6
Number of MII oocytes vitriﬁed
(mean+SD)
6.3+2.8
CCOC, cumulus corona oocyte complex; MII, metaphase II.
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primary outcomes excluded the predeﬁned non-inferiority margin of
17%.
No correlations were found by logistic regression analysis between
potential confounding variables (female age, rank of trial, baseline FSH,
stimulation protocol, total dose of gonadotrophin, days of stimulation,
number of cumulus corona cell oocyte complexes retrieved, number
of MII obtained) and primary outcome measures. Moreover, the prob-
ability of obtaining at least one fertilized oocyte per cycle was not sig-
niﬁcantly different for fresh and vitriﬁed oocytes (P ¼ 0.48 by
McNemar’s test).
The mean embryo score obtained in the fresh ICSI group and in the
vitriﬁed/warmed ICSI group was also similar (1.39+1.40 and 1.48+
1.47, respectively) (P ¼ 0.68).
Discussion
The aim of this study was to compare the in vitro performance of fresh
and vitriﬁed oocytes post-ICSI procedure. A randomized trial on
sibling oocytes was set up. Oocyte fertilization was not signiﬁcantly
different when calculated per warmed and per injected oocytes. More-
over, embryo development was similar in the two groups.
Vitriﬁcation procedure was recently introduced in our laboratory as
an alternative to slow freezing for oocyte cryopreservation. This
choice was based on recent evidences that the vitriﬁcation procedure
is less invasive, better preserves oocyte physiology as compared with
slow freezing (Gardner et al., 2007) and can obtain excellent clinical
outcomes (Kuwayama et al., 2005; Selman et al., 2006; Lucena
et al., 2006; Antinori et al., 2007; Kuwayama 2007; Yoon et al.,
2007; Cobo et al. 2008b, c, Chian et al., 2008; Sher et al., 2008;
Kim et al., 2009; Nagy et al., 2009).
Different approaches in the vitriﬁcation procedure have been
described for the human oocyte, embryo and blastocyst stages (see
review by Vajta and Nagy, 2006). Although these approaches work
on the same principle, they differby typeand concentrationof cryopro-
tectants and/or for device used. In this study, the protocol ﬁrstly
described by Kuwayama et al. (2005, 2007) was applied. Accordingly,
the combination of EG and DMSO at a ﬁnal total concentration of
30% and 0.5 M sucrose were used as cryoprotectants. Oocytes were
loaded, vitriﬁed and stored in Cryotops (Kitazato). To achieve vitriﬁca-
tion, oocytes werecovered byathin ﬁlm of cryoprotectantmixtureand
exposedto directcontactwithliquid nitrogen.Althoughthis isthemost
efﬁcient approach to maximize cooling rates and minimize biological
damages to the oocytes (Vajta et al., 2009, in press), it potentially
exposes the cells to risk for contamination (Bielanski et al., 2000). The
resultsreportedinthis studyarehoweverstrictlyrelatedtothe vitriﬁca-
tion method used, other vitriﬁcation approaches in our hands were sig-
niﬁcantly less effective (data not shown). We are now evaluating the
possibilitytoeliminatethecross-infectionpotentialriskwithoutmodify-
ing the principles of the protocol. This is possible with the use of highly
........................................................................................
Table II Clinical outcomes of cycles performed with
vitriﬁed/warmed oocytes
Patients included
(N 5 40)
Number of warmed oocytes
(mean+SD)
3.1+0.30
Number of embryos transferred
(mean+SD)
2.3+0.88
Number of embryo transfer performed
(%)
39/40 (97.5)
Clinical pregnancy rate per cycle (%) 15/40 (37.5)
Clinical pregnancy rate per transfer (%) 15/39 (38.5)
Ongoing pregnancy rate per cycle (%) 12/40 (30.0)
Ongoing pregnancy rate per transfer (%) 12/39 (30.8)
Implantation rate (%) 19/93 (20.4)
Ongoing implantation rate (%) 16/93 (17.2)
.............................................................................................................................................................................................
Table III Primary and secondary outcomes measures: fertilization, pronuclear morphology, embryo development and
embryo morphology of fresh and vitriﬁed sibling oocytes
Fresh ICSI Vitriﬁed/Warmed
ICSI (%)
Absolute difference
(%) (95% CI)
OR (95% CI) P
Fertilization (2PN) per sibling oocyte 100/120 (83.3)
b 95/124 (76.6)
a 26.73 (216.6 to 3.39) 0.65 (0.33 to 1.29) 0.20
Fertilization (2PN) per injected oocyte 100/120 (83.3)
b 95/120 (79.2)
b 24.17 (214.0 to 5.7) 0.76 (0.37 to 1.53) 0.50
Normal 2PN morphology 96/100 (96.0)
c 86/95 (90.5)
c 25.47 (213.4 to 1.84) 0.39 (0.08 to 1.49) 0.16
1PN oocytes 3/120 (2.5)
b 6/120 (5.0)
b 2.5 (22.82 to 8.22) 2.05 (0.42 to 12.9) 0.50
3PN 1/120 (0.83)
b 2/120 (1.66)
b 0.83 (23.09 to 5.1) 2.01 (0.10 to 119.9) 1
Degenerated oocytes post-ICSI 1/120 (0.83)
b 4/120 (3.34)
b 2.51 (21.75 to 7.47) 4.08 (0.39 to 203.5) 0.37
Day 2 embryo development 100/100 (100)
c 93/95 (97.9)
c 22,11 (27.3 to 1.9) 0.0 (0.00 to 0.23) 0.24
Excellent quality embryos 52/100 (52.0)
d 49/95 (51.6)
d 20.43 (214.2 to 13.3) 0.98 (0.53 to 1.79) 0.90
Good quality embryos 38/100 (38.0)
d 41/95 (43.2)
d 5.16 (28.49 to 18.6) 1.24 (0.67 to 2.28) 0.47
Fair/poor quality embryos 10/100 (10.0)
d 3/95 (3.16)
d 26.84 (214.6 to 0.42) 0.29 (0.05 to 1.19) 0.10
aPercentages, expressed per warmed oocyte.
bPercentages, expressed per inseminated oocyte.
cPercentages, expressed per 2PN fertilized oocyte.
dPercentages, expressed per cleaved oocyte.
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nitrogen by ultraviolet irradiation (Parmegiani et al., 2009a, b) allowing
retention of the directcontact, and hermetical devicesfor storage(pre-
cooled straws heat-sealed and stored in liquid nitrogen containers)
(Vajta et al., 1998, 2009, in press). Alternatively, for the latter, dry
systems have been proposed (Cobo et al., 2008c).
Some other technical aspects of this study must be highlighted. The
vitriﬁcation procedure was performed immediately after denudation
and always between 37 and 40 h post-hCG administration. It was
shown that timing is a crucial aspect when dealing with oocytes
prior to insemination (Parmegiani et al., 2008, 2009a, b). Conversely
to pronuclear, embryo and blastocyst stage, oocytes are developmen-
tally arrested (at metaphase II stage) and thus much more sensitive to
in vitro culture (Yanagida et al., 1998; Dozortsev et al., 2004). Long
incubation periods, prior to cryopreservation, presumably affects
oocyte competence. Moreover, after denudation, oocytes are particu-
larly vulnerable to suboptimal in vitro conditions (Edwards et al., 1998).
These drawbacks, not strictly related to cryopreservation itself but
often associated with it, may explain part of the low success rate gen-
erally reported with oocyte freezing. To minimize oocyte stress, the
denudation process was performed in a chamber with controlled
temperature and gas atmosphere, in our laboratory (L-323, Ksystems).
In this way, the randomization process was also performed without
exposing the oocytes to suboptimal conditions. It was decided not
to observe the oocytes under the inverted microscope for ﬁne
morphological assessment in this study. This extra manipulation
was considered potentially harmful. According to our experience
(Rienzi et al., 2008) only oocytes with determined abnormal
morphological features, assessable under the stereomicroscope at
40 magniﬁcation, were considered severely compromised and
were not included in the study.
After warming, the oocytes were cultured for 2 h before insemina-
tion. This period was considered necessary to allow the oocyte cyto-
skeletal apparatus to fully restore after vitriﬁcation, and in particular
the meiotic spindle. We previously showed that oocyte meiotic
spindle needs 3 h to fully reform after slow freezing procedure
(Rienzi et al., 2004). This observation was conﬁrmed by other
studies using different oocyte freezing and/or vitriﬁcation procedures
(Bianchi et al., 2005; Coticchio et al., 2007; Cobo et al., 2008a).
Spindle recovery seems however to be faster after vitriﬁcation than
slow freezing (Larman et al., 2007; Chen and Yang, 2009). To mini-
mize oocyte ageing post-warming it was decided to reduce the in
vitro culture period prior to insemination from 3 to 2 h. Recent evi-
dences suggest that this period could further diminish to 1 h where
the higher rate of normal spindle conﬁguration is observed (Bromﬁeld
et al., 2009, in press).
The general idea of the study was thus to minimize extra stress on
oocytes often related with cryopreservation procedures, namely: (i)
long exposure to Hepes-buffered media, with uncertain temperature
control, for oocyte denudation and selection under the inverted
microscope, (ii) prolonged oocyte in vitro culture without the protec-
tion of cumulus and corona cells, (iii) oocyte ageing. In this way, by
using randomized sibling oocytes, the only difference between the
fresh and the vitriﬁed group was the vitriﬁcation procedure itself fol-
lowed by 2 h of in vitro culture.
According to our results, embryo development up to Day 2 is not
affected by vitriﬁcation procedure. Oocyte survival rate was higher
than 95%. The number of oocytes degenerated during warming pro-
cedure was negligible and did not affect the overall fertilization rate.
Although some, non-signiﬁcant, differences in pronuclear morphology
were observed, embryo quality was similar in the two groups. The
percentage of top quality embryos per fertilized oocyte was about
52% in fresh and vitriﬁed group of oocytes. These observations are
further conﬁrmed by the clinical outcomes obtained. Although, the
evaluation of pregnancy and implantation rates were beyond the
purpose of this study, it is interesting to report the promising clinical
results recorded in the analysed warming cycles. An ongoing clinical
pregnancy of 30% and an ongoing implantation rate of 17% were
obtained in our population of infertile couples subjected to severe
legal restrictions (where only three vitriﬁed oocytes could be insemi-
nated per cycle). Thus, the ongoing implantation rate per warmed
oocytes was 12.9% (16/124). Moreover four ongoing pregnancies
(30.7%) were obtained in women aged .38 years. It cannot be
excluded that endometrium receptivity may also be involved in suc-
cessful implantation of embryos derived from vitriﬁed oocytes. By
transferring embryos in a natural unstimulated cycle, synchronization
of embryo and endometrial development can be, in fact, probably
better obtained (Ubaldi et al., 1997).
We believe that these results will help the spread of vitriﬁcation for
human oocytes cryopreservation. This possibility is particularly impor-
tant to overcome legal and ethical issues related to embryo storage.
Moreover, this study demonstrates that the same number of
oocytes is needed in fresh and vitriﬁed cycles to obtain similar
results in terms of embryo development. The number of oocytes to
be warmed per cycle should thus be chosen accordingly. We
believe that this ﬁnding is particularly important in oocyte donation
programmes where a limited number of oocytes are available for reci-
pients. Moreover, in order to avoid the production of supernumerary
embryos and thus the risk of double vitriﬁcation, a limited number of
oocytes should be warmed per cycle in patients who have cryopre-
served oocytes because they are at risk of premature ovarian failure.
To our knowledge, this is the ﬁrst clinical trial, designed in a pro-
spective randomized way, which demonstrates the efﬁcacy of the vitri-
ﬁcation procedure to maintain oocyte competence to develop in vitro,
in a population of infertile patients. We believe that this study strongly
supports the laboratory efﬁcacy of the technique. Further studies, per-
formed on a larger scale, are however needed to conﬁrm clinical out-
comes of vitriﬁed oocytes and the safety of the technique.
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